UPDATE: Novavax (NVAX) Target Raised to $12 at Wedbush; Analyst Expects Positive Data on RSV-F Vaccine
Tweet Send to a Friend
(Updated - December 16, 2013 11:16 AM EST)
Wedbush maintained an Outperform rating on Novavax (NASDAQ: NVAX) and raised ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush maintained an Outperform rating on Novavax (NASDAQ: NVAX) and raised ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
